Atrium Therapeutics, Inc. Common Stock (RNA) — Cash Flow Reinvestment Rate
Atrium Therapeutics, Inc. Common Stock (RNA) has a Cash Flow Reinvestment Rate of 3.15x as of December 2023, reinvesting $51.90 Million (capex $863.00K plus investments $51.04 Million) from operating cash flow of $16.50 Million. Explore cash flow conversion of Atrium Therapeutics, Inc. Common Stock to assess how effectively this company generates cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Cash Flow Reinvestment Rate (2019–2019)
Historical reinvestment intensity for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. Explore RNA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year capital reinvestment analysis for Atrium Therapeutics, Inc. Common Stock. For live market cap and broader valuation context, see RNA market cap.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.19x | $470.00K | $2.49 Million | $235.00K | — |